2024-03-29T12:08:10Zhttps://repositori.uji.es/oai/requestoai:repositori.uji.es:10234/1833752023-10-31T11:07:12Zcom_10234_7013com_10234_9col_10234_8638
00925njm 22002777a 4500
dc
Mishra, Pooja
author
Pawar, Rajendra-Prasad
author
Bose, Devasish
author
Durgbanshi, Abhilasha
author
Albiol Chiva, Jaume
author
Vives-Peris, Vicente
author
Esteve-Romero, Josep
author
Jain, Abhishek
author
2019
Aim: The macrolide antibiotic rifampicin is prescribed against several infections, like tuberculosis disease. This drug decays to rifampicin quinone. Results/methodology: The biological fluids were diluted in a micellar solution and directly injected. Using a C18 column and a mobile phase of 0.15 M SDS-6% 1-pentanol phosphate-buffered at pH 7, running at 1 ml/min, the analytes were resolved in less than 15 min. The detection was by absorbance at 337 nm. Method was validated by the guidelines of the European Medicines Agency. Decomposition of rifampicin to rifampicin quinone was also studied. Discussion/conclusion: Procedure is rapid, easy-to-handle, economic, eco-friendly and with a high sample throughput. It was successfully used to monitor rifampicin in the plasma and urine of tubercular patients.
MISHRA, Pooja, et al. Stability studies of rifampicin in plasma and urine of tuberculosis patients according to the European Medicines Agency Guidelines. Bioanalysis, 2019, vol. 11, no 08, p. 713-726
1757-6180
1757-6199
http://hdl.handle.net/10234/183375
https://doi.org/10.4155/bio-2018-0174
plasma and urine samples
rifampicin
stability studies
tuberculosis
validation
Stability studies of rifampicin in plasma and urine of tuberculosis patients according to the European Medicines Agency Guidelines